Hiperprolactinemia inducida (Prolactinomas) en la mujer transexual. Parte 1 (página 2)

18.  Fainstein Day P, Guitelman M, Artese R, et al. Retrospective multicentric study of pituitary incidentalomas. Pituitary. 2004;7(3):145-148.

19. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377-382.

20. Fernández-Balsells MM, Murad MH, Barwise A, et al. Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2011;96(4):905-912.

21. Gao R, Isoda H, Tanaka T, et al. Dynamic gadolinium-enhanced MR imaging of pituitary adenomas: usefulness of sequential sagittal and coronal plane images. Eur J Radiol. 2001;39(3):139-146.

22. Guillam MP, Molitch ME, Lombardini G, Colao A. Advances in the treatment of prolactinomas. Endocrine Reviews 2006; 27: 485-534.

23. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med. 1994;120(10):817-820.

24. Heaney AP, Fernando M, Melmed S. Functional role of estrogen in pituitary tumour pathogenesis. J Clin Invest 2002; 109:277-83.

25.  Ishida M, Takahashi W, Itoh S, et al. Estrogen actions on lactotroph proliferation are independent of a paracrine interaction with other pituitary cell types: a study using lactotroph-enriched cells. Endocrinology 2007; 148: 3131-9

26. Jeffcoate WJ, Pound N, Sturrock NDC, Lambourne J. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 1996; 45:299-303.

27. Jequir A, Crich HC, Ansel ID. Clinical findings and testicular histology in three hyperprolactinaemic infertile men. Fertil Steril 1979; 32:525-8.

28. King JT Jr, Justice AC, Aron DC. Management of incidental pituitary microadenomas: a cost-effectiveness analysis. J Clin Endocrinol Metab. 1997;82(11):3625-3632.

29. Klibanski A, Zerves NT. Diagnosis and management f hormone secreting pituitary adenomas. N Engl J Med 1991;324:811.Steroid Biochem Mol Biol 1994;51:183-9.

30. Kochman K, Joseph JA, Blackman MR, et al. Impaired down-regulation of pituitary dopamine receptors by estradiol in aged rats. Proc Soc Exp Biol Med 1989; 192: 23-6

31. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab. 2001;86(9):4072-4077.

32. Lafeber M, Stades AM, Valk GD, Cramer MJ, Teding van Berkhout F, Zelissen PM. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol. 2010;162(4):667-675.

33. Mancini T 1, Casanueva FF, Giustina A. La hiperprolactinemia y prolactinomas. Endocrinol Metab Clin Norte Am 2008 Mar; 37 (1): 67-99

34. McNelly AS, Sharpe RM, Davidson DW. Hyperprolactinaemic male infertility. Fertil Steril 1976;27:1425-7.

35. Melmed S, Casanueva FF, Hoffman AR, et al.; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288.

36. Molitch Mark E. Pathologic Hyperprolactinemia. Endocrin Metab Clin North Am 1992;21:877-900.

37. Molitch Mark. Dopamine Resistance of Prolactinoma: Pituitary 2003; 6:19-27.

38. Rennert J, Doerfler A. Imaging of sellar and parasellar lesions. Clin Neurol Neurosurg. 2007;109(2):111-124.

39. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history f untreated hyperprolactinemia: a prospective analysis.J Clin Endocrinol Metab 1989;68:412-8.

40. Schlechte JA. Long-term management of prolactinoma. J Clin Endocrinol Metab 2007; 92: 2861-2865.

41. Schlechte Janet. Prolactinoma. N Engl J Med 2003; 349:2035-2041.

42. Snyder PJ. Gonadotroph cell adenomas. In: Melmed S, ed. The Pituitary. 3rd ed. Amsterdam: Elsevier; 2011:637-651..

43. Spady TJ, McComb RD, Shull JD. Estrogen action in the regulation of cell proliferation, cell survival, and tumorigenesis in the rat anterior pituitary gland. Endocrine 1999; 11: 217-33

44. Teip CS. The regression of oestradiol-induced pituitary tumours in the rat. J Pathol 1983; 141: 29-40

45. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171-1177.

46. Vance ML. Diagnosis, management, and prognosis of pituitary tumors. In: Thapar K, Kovacs K, Scheithauer BW, Lloyd RV, eds. Diagnosis and Management of Pituitary Tumors. Totowa, N.J.: Humana Press; 2001:165-172.

47. Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol. 2003; 2(1):23-32.

48. Vilar L, Freitas MC, Naves LA, et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest. 2008;31(5):436-444.

49. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994;331(14):904-909.